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Summary 
When administered at or near the initiation of experimental intracellular infection caused by 
Leishmania major, Toxoplasma gondii,  or Cryptococcus neoformans, treatment with the immuno- 
regulatory cytokine interleukin 12 (IL-12), induces protective antimicrobial activity. In contrast, 
once infections are established, IL-12 exerts considerably less or no effect in the face of a suppressive 
Th2 cell-associated response (L. major) or rapidly progressive fatal infection (T. gondii). To test 
the efficacy of IL-12 in an established intracellular protozoal infection but under quite different 
immunologic conditions (Thl cell response, acquired resistance), L. donovani-infected  BALB/c 
mice were treated starting 2 wk after challenge coincident with the onset of the Thl cell response. 
In this environment, 7 d of IL-12  treatment reduced liver parasite  burdens by 47%,  an effect 
comparable to that induced by exogenous interferon (IFN) %  The in vivo mechanism responsive 
to IL-12 was complex, and required both CD4 + and CD8 + T cells as well as natural killer cells 
and the action of multiple endogenous antileishmanial cytokines (IFN-% IL-2, tumor necrosis 
factor oe). Early treatment with IL-12 before the expression of the Thl cell response was also 
effective and induced an accelerated, near-cure response via an IFN-'lr-dependent mechanism. 
These results extend the antimicrobial-inducing capacity of IL-12 beyond prophylaxis by indicating 
that IL-12  can exert clear-cut therapeutic activity in an established intracellular infection. 
N 
'umerous recent reports have identified the pleiotropic 
cytokine, IL-12, as a critical component of the early 
events that initiate successful cell-mediated antimicrobial de- 
fense (1-3). The role and/or effect of IL-12 has thus far been 
tested in four models of intraceUular infection caused by Le/sh- 
mania major (4,  5),  Toxoplasma gondii (6-8), Listeria mono- 
cytogenes (9), and Cyptococcus neoformans (10). Results from 
these models suggest that the role of endogenous IL-12 and 
the treatment effect of exogenous IL-12 are both most prom- 
inent at or near the time infection is first introduced (4, 5, 
7). Indeed, when tested after the initial stage of host-parasite 
interaction in two of these models, IL-12 in exogenous form 
exerted considerably less activity in L. major infection (4, 5) 
and no effect in acute toxoplasmosis (7). These latter results 
have prompted the impression that while IL-12 appears  to 
be of clear-cut immunoregulatory importance (1-3) and effec- 
tive early on or as prophylaxis (4-7,  10), there may never- 
theless be a narrow therapeutic window for IL-12 in such 
infections. 
Specific features of the preceding models of uncontrolled 
progressive infection (4, 5, 7), however, likely influenced the 
efficacy of delayed IL-12 treatment: (a) the rapid establish- 
ment of an overwhelming and uniformly fatal infection in 
the acute T gondii model (7), and (b) the prompt emergence 
of a particularly suppressive Th2 cell-assodated response which 
characterizes and propagates L.  major infection in BALB/c 
mice (4, 5). The results in these selected models, therefore, 
have left open the question of whether IL-12 can act ther- 
apeutically in other settings, for example, in an established 
but not fatal intracellular infection and/or in an intracellular 
infection associated with acquired resistance and a Thl cell- 
rather than a Th2 cell-associated response. Since our model 
of visceral leishmaniasis fulfills these latter criteria (11, 12), 
we treated L. donovani-infected BALB/c mice with IL-12 to 
test its in vivo activity under these quite different immuno- 
logic conditions. 
Materials and Methods 
Visceral Infection.  20-30-g  female  euthymic  BALB/c and 
C57BL/6 beige mice (Charles River Breeding Laboratories, Wil- 
mington, MA) and athymic (nude) BALB/c mice (Life Sciences, 
Inc., St. Petersburg, FL) were infected by tail vein with 1.5  x  107 
L. donovani  amastigotes maintained in hamsters (11). Visceral infec- 
tion was assessed microscopically in liver imprints, and liver para- 
site burdens are expressed  as Leishman-Donovan units (LDU) (11). 
Tissue granuloma development was examined using formalin-fixed, 
stained liver sections (11). 
Treatment with IL12 and IFN-T.  Groups of three to five mice 
were treated for 7 d with 1 #g/d of murine rlL-12 (7.8  x  106 
U/mg; Genetics Institute,  Cambridge, MA) (4) and/or 2  x  10  s 
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Thousand Oaks, CA) suspended in saline containing 1 mg/ml of 
BSA (13). Treatment was given continuously via subcutaneously 
implanted osmotic  pumps (Alzet model 2001; Alza Corp., Palo  Alto, 
CA) (12) which deliver  drug for 7 d (12a). Preliminary  experiments 
indicated that IL-12 delivered at 1 #g/d by pump for 7 d was as 
effective as seven consecutive daily intraperitoneal injections of 1 
/~g of 1I.-12 (4, 5) (data not shown). Pumps were implanted 4 h 
after L. donovani challenge  to test early (prophylactic)  effects  or 14 d 
after challenge to determine therapeutic activity in established in- 
fection. Treatment with pump-delivered  saline/BSA alone had no 
effect as in prior studies (13). 
Treatment with Cell-defleting and Anticytokine Antibodies.  Using 
previously described preparations and administration schedules 
(14-16) (see legends to Tables 1 and 2 and Fig. 1), IL-12-treated 
mice were injected intraperitoneally with: (a) 1 ml of hybridoma 
culture supernatants containing rat anti-mouse mAb GK1.5 (anti- 
CD4, American Type  Culture Collection [ATCC, Rockville, MD] 
TIB 207, 8/~g/ml of IgG), 53-6.72 (anti-CD8, ATCC TIB 105, 
11.6/~g/ml of IgG), and S4B6.1 (anti-IL-2, 12.5/~g/ml of IgG), 
or 25/~g of  normal rat IgG (Sigma Chemical Co., St. Louis, MO); 
(b) 40/~1 of NK cell-depleting rabbit antiasialo GM1 antiserum 
(Wako Bioproducts, Richmond, VA) (15); or (c) 0.2 ml containing 
normal rabbit serum, rabbit anti-mouse TNF-~ antiserum (1.5 x 
10  s neutralizing  U/ml)  (16), or rabbit  anti-mouse  IFN-3~ an- 
tiserum raised against routine rlFN-3,. At a dilution of 1:10,000, 
the latter preparation neutralized the activity of 10 U of rlFN-3, 
in an ELISA (Endogen Inc., Boston, MA). Fluorescence analysis 
of spleen cells (14) after three consecutive daily injections of anti- 
CD4 or anti-CD8 mAb indicated depletion of the targeted T call 
subset by 89-93%  (data not shown). 
Results and Discussion 
Effect of  lL-12 Treatment in Established Visceral  Infection.  In 
euthymic BALB/c mice, L. donovani multiplies logarithmi- 
cally within macrophages of the liver and spleen during the 
first 2-4 wk after challenge (11). By week 4, T  cell-depen- 
dent acquired resistance mediated by the Thl cell-associated 
cytokines, IFN-'y and IL-2 (12, 15, 17), develops, visceral in- 
fection comes under control, and organ parasite burdens de- 
dine (11). To test the effect of IL-12 under these conditions 
in established visceral infection, pump treatment was begun 
2 wk after L. donovani challenge and continued for 7 d. As 
shown in Table 1, IL-12 at 1 #g/d readily induced leishmani- 
cidal activity, and liver parasite burdens decreased by 47% 
(day 14 vs. day 21). Treatment with 0.1/~g/d produced a similar 
effect, whereas 0.01 ~g/d did not induce leishmanicidal ac- 
tivity (data not shown). The effect of pump IL-12 was com- 
parable  to the 40% killing achieved by 7 d of pump treat- 
ment with 2  x  10  s  U/d  of IFN-7  (data not  shown),  a 
cytokine with already well-demonstrated antileishmanial ac- 
tivity (13). 2-wk infected mice were also treated for 7 d with 
IL-12 (1 ~g/d) plus IFN-3' (2  x  105 U/d) by inserting two 
pumps. However, combination cytokine treatment did not 
achieve effects beyond those induced by IL-12 alone (two ex- 
periments, not shown) suggesting that exogenous IL-12 and 
IFN-3/may use or stimulate the same antileishmanial mech- 
anism or target effector cells. The granulomatous response 
in the liver, the histologic correlate of acquired resistance in 
this model (11), can be upregulated by treatment with some 
Table  1.  Effect  of IL-12  Treatment in Established Infection and Role of T  Cells and NK Cells 
Liver parasite burden (LDU) 
Mice and 
treatment"  day 14  day 21  Percent killing* 
Euthymic BALB/c 
Untreated  1,219  _+  72 (16)  2,157  _+  155 (16)  0 
IL-12  647  _+  51  (18)  47 
+  anti-CD4  1,802  _+  115 (6)  0 
+  anti-CD8  2,321  +  147 (6)  0 
+  rat IgG  810  +  76 (9)  34 
+  anti-asialo GM1  1,481  _+  110 (6)  0 
+  rabbit serum  670  +_ 65 (6)  45 
Nude BALB/c 
Untreated  1,787  _+  118 (13)  3,483  _+  154 (13)  0 
IL-2  3,964  _+  250 (12)  0 
C57BL/6 Beige 
Untreated  2,105  _+  120 (6)  2,955  _+  145  (6)  0 
IL-12  1,397  +  104 (6)  34 
" 2 wk after L. donovani infection,  liver parasite burdens were determined, and pumps delivering 1/tg/d of IL-12 were then inserted on day 14. 
Anti-CD4, anti-CD8, and control rat IgG injections were given on days 11, 12, 13, 17, and 19 (14, 15). Antiasialo  GM1 antiserum and normal 
rabbit serum were injected on days  11 and 17 (14). Results  are from two to four experiments,  and indicate  mean _+ SEM values  for (n) mice  per group. 
*  Percent killing =  day 14 LDU  -  day 21 LDU  + day 14 LDU  x  100 (13). 
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Liver parasite burdens (LDU) 
Treatment  day  14  day 21  Percent killing 
None (control)  1,280  _+ 46 (12)  2,488  +  123 (12)  0 
IL-12  771  _+ 78 (12)  40 
+  anti-IFN-3,  2,936  _+  160 (10)  0 
+  anti-TNF-c~  2,820  _+  125  (11)  0 
+  rabbit  serum  886  +  86 (12)  31 
+  anti-IL-2  1,624  _+  115 (6)  0 
+  rat IgG  866  _+  106 (6)  32 
* Pumps delivering 1 #g/d of IL-12 were inserted 2 wk after infection in euthymic BALB/c mice. Each of the indicated preparations were injected 
into IL-12-treated mice 2 h before pump insertion and repeated as follows: anti-IFNw on day 17 (17), and anti-TNF-tx, normal rabbit serum, anti- 
IL-2, and rat IgG on days 17 and 20 (15, 16). Results are from two to three experiments,  and indicate mean _+ SEM values for (n) mice per group. 
(12a,  15) but not all (13) exogenous cytokines that induce 
antileishmanial activity. Hepatic granuloma assembly, how- 
ever, was not altered by IL-12 administration (data not shown). 
Cells Required.for In Vivo Responsiveness to IL-12.  In con- 
trast to euthymic animals, 2-wk infected nude BALB/c mice 
failed to respond to IL-12 (Table 1) indicating that host T 
cells were required and suggesting that NK cells (retained 
in nude mice [6]) were not suffldent by themselves to mediate 
the antileishmanial effects of exogenous IL-12. Treatment of 
euthymic BALB/c mice with T  cell subset-depleting mAb 
indicated that both CD4 + and CD8 + cells were required for 
optimal IL-12-induced activity (Table 1). Although the results 
in nude mice suggested that NK cells alone were not sufl~dent 
to mediate the effect of IL-12, treatment of euthymic mice 
with NK call-depleting antiasialo GM1 antiserum revealed 
dear-cut evidence (Table  1) that NK cells were indeed in- 
volved and interacted with CD4 + and CD8 + cells.  Thus, 
NK cells represented a third host defense cell required for 
optimal in vivo responsiveness to exogenous IL-12. Since 2-wk 
infected C57BL/6 beige mice also responded to IL-12 (Table 
1), the role identified for NK cells did not appear to involve 
cytotoxic activity (18). 
Endogenous Cytokines Required.for Response to IL-12.  Pre- 
vious studies in this model have demonstrated that L. donovani 
triggers the secretion of IFN-% IL-2, TNF-ot, and that ac- 
quired resistance involves the participation and interaction 
of each of these endogenous cytokines (15-17).  Since IL-12 
can induce IFN-3, and IL-2 (1, 19) as weU as interact with 
IL-2 and TNF-o~ to enhance IFN-'y secretion (1, 19), we treated 
mice with various anticytokine preparations at the time of 
IL-12 administration. The results in Table 2 indicate that the 
leishmanicidal activity induced by IL-12 is multi-cytokine 
dependent and in a likely complex fashion (1, 19, 20) involves 
endogenous IFN-%  IL-2,  and TNF-ol. 
Effect of Early IL-12  Treatment.  While L. donovani pro- 
vokes a predominant Thl cell-associated response in BALB/c 
mice, this response is not detectable until >-, 10 d after infec- 
tion as judged by the emergence of IFN-3' and IL-2 mKNA 
expression in the tissues (12). Therefore, we completed these 
treatment experiments by determining whether the presence 
of IL-12 at the initiation of L. donovani infection (before the 
induction of the Thl cell response) could also modify out- 
come. Such early, essentiaUy prophylactic treatment strikingly 
modifies the course of L. major infection apparently by in- 
hibiting the development of suppressive Th2 cell-associated 
responses and promoting protective Thl ceil responses largely 
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Figure  1.  Effect of early IL-12 treatment during 
week I  on the course of L. donovani infection in eu- 
thymic BALB/c mice. (A) Pumps delivering 1 #g/d 
of IL-12 for 7 d (@) were implanted 4 h after chal- 
hnge; (O) untreated controls. ILd2-treated mice were 
also injected with either  anti-IFN-3, antiserum (A) 
or normal rabbit serum (D) three times during week 
1:2 h, 3 d, and 7 d after pump insertion. (/3) Effect 
of early treatment during  week 1 with I1.,12  vs. IFN-% 
4 h after infection, pumps delivering 7 d of either Ib12 
(1 ~g/ml) (e) or IFN-~ (2 ￿  105 U/d) (A) wm im- 
planted; (O) untreated mice. Results in (A) and (/3) 
are from two to four experiments, and indicate mean 
•  SEM values for 6-15 mice per group. 
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IL-12 treatment  during week 1 only clearly enhanced con- 
trol over visceral L. donovani;  this effect was evident by week 
2 and fully expressed by week 4. Although the effect of early 
IL-12 treatment was inhibited by simultaneous injections of 
anti-IFN-y (Fig.  1 A), administration  of exogenous IFN-3' 
alone during week 1 did not achieve similarly sustained anti- 
leishmanial activity (Fig.  1 B). This latter observation sug- 
gested effects of early IL-12 treatment in addition to the in- 
duction of endogenous  IFN-3,. 
Together, these results indicate that IL-12 is active as treat- 
ment in a firmly established systemic intracellular  infection 
caused by a pathogen that exclusively resides within visceral 
macrophages (11). In view of the demonstrated role of en- 
dogenous  IFN-3'  in  this  model  (17)  and  IFN-q,'s  direct 
macrophage-activating leishmanicidal  effects (13), the capacity 
of IL-12 by itself or with IL-2 and TNF-ol to induce T cells 
and NK cells  to secrete IFN-3' (1,  19,  20)  seems likely to 
represent a primary action for IL-12. This conclusion, how- 
ever, does not exclude the possibility that in established in- 
fection IL-12 treatment also further promotes or accelerates 
other effects of the generalized Thl cell-associated response 
which L. donovani  infection provokes in this model (12, 15, 
17). Indeed, the capacity of early IL-12 treatment to act be- 
fore the Thl cell response becomes detectable but still effec- 
tively influence the subsequent course of visceral  infection 
supports other  actions as well. 
Controlled clinical trials have now shown IFN-3/to be an 
effective adjunct  when  used with  conventional  antimony 
chemotherapy in patients with visceral leishmaniasis  (21, 21a). 
Thus, the present results suggest that by acting as an inducer 
of endogenous IFN-% IL-12 may have also a future role as 
an adjunct to chemotherapy in the management of this and 
perhaps other IFN-3,-responsive intracellular infections (22). 
Whether exogenous IL-12 can influence what appears to be 
a Th2 cell-associated response in human visceral leishmani- 
asis (23-25) and restore suppressed IFN-q,-generating capacity 
(23) are two important  questions that remain to be tested. 
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